The Road Ahead in Molecular Oncology for Advanced Non–Small Cell Lung Cancer

Howard (Jack) West, MD


November 16, 2021

H. Jack West, MD, reflects on the evolution of molecular oncology and the increased expectations for survival in advanced non–small cell lung cancer. Over the course of his career, Dr West has witnessed 'a splintering fundamental change' from the period in which patients with advanced lung cancer were viewed as a monolithic entity and managed with a two-drug chemotherapy combination with little benefit. In our current era, Dr West feels that another fundamental change is needed to apply a rigorous standard of molecular testing.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.